Mon, Aug 15, 2022
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Venture capital-backed deals in healthtech companies hit $8.2bn in Q1 2020

Friday, May 29, 2020
Opalesque Industry Update - Prior to the outbreak of COVID-19, healthtech was already a sector of increasing interest among investors, said Preqin. But as a result of COVID-19, more alternative assets professionals are looking for opportunities in the healthtech sector, and there has been an uptick in venture capital dealmaking in the space.

Between January and March 2020, the total value of global venture-backed healthtech deals jumped by 76% from Q1 2019 reaching $8.2bn, the highest quarterly total on record. Activity has been dominated by North America, comprising 56% of the total number of deals, followed by Europe with 21% and Asia with 17%.

The largest venture-backed healthtech deal completed in Q1 2020 was the $285mn Series E financing held by ClassPass Inc. This momentum has continued into Q2, with a further $3.2bn in healthtech deals made since the start of April - at this pace, 2020 will be a record year for the sector by some distance.

Christopher Beales, Private Equity Spokesperson: "Healthtech was already an area of some interest to venture capital investors, as Preqin discussed at the start of the year. But the COVID-19 pandemic has thrown the potential of the sector into sharp relief. Remote consultations, prescription delivery, digital therapeutic and wellness classes - demand for next-generation healthcare solutions has boomed. As such, startups and investors are jumping to try and meet that need, and a sector that was already expanding has been given a real shot of adrenaline."

Key Healthtech Deals Facts:

• In our April 2020 survey of over 100 investors active in alternative assets, 36% said that they are targeting healthcare-focused investments in 2020 because of COVID-19's impact.

• Global venture-backed healthcare deal value increased from $4.7bn in Q1 2019, to $8.2 in Q1 2020.

• Regionally, in Q1 2020, 239 deals were completed in North America, 87 in Europe and 73 in Asia.

• The largest venture-backed healthtech deal completed in Q1 2020 was the $285mn Series E financing held by ClassPass Inc.

• In Q2 2020, as at 18th May 2020, 158 healthtech deals have been completed with a value of $3.2bn.

Article source - Opalesque is not responsible for the content of external internet sites

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Opalesque Exclusive: Hong Kong manager expects additional tailwind in Asian markets[more]

    B. G., Opalesque Geneva: The Asia equity markets have not been at their best so far this year, with the MSCI Asia index down almost 13% YTD, but many managers remain buoyant about the region, as in

  2. Opalesque Exclusive: Emerging markets persist despite headwinds[more]

    Bailey McCann, Opalesque New York: Emerging markets have been under significant pressure since the start of the year, but there are some nascent trends that suggest that things could be getting better. Emerging markets firm Gramercy Fund Management recently released its third quarter outlook and

  3. Opalesque Exclusive: Castle Hall's DiligenceExchange free Transparency Reports cover 100 managers with $10tn of assets[more]

    Matthias Knab, Opalesque for New Managers: Managers and investors can get free access to DiligenceExchange here: https://bit.ly/DXCInfo Castle Hall, the Du

  4. Other Voices: ESG exuberance is at all-time highs. But will investors buy?[more]

    As investors increase their focus on mission-based investing, they continue to grapple with ESG and what it means to them. By David Shalom, Director of Capital Introductions at Pershing Innovation. New investment solutions. That's how managers deliver value and attract new inve

  5. Opalesque Exclusive: This European mezzanine debt strategy offers equity-like returns with downside protection[more]

    B. G., Opalesque Geneva for New Managers: Mezzanine financier SIG-i operates in a relatively uncrowded space by proactively manufacturing financing solutions as an alternative to traditional debt and equity instrume